9 07 June 2021 Semaglutide 2.4 mg approval in the US Investor contact information Share information Novo Nordisk’s B shares are listed on the stock exchange in Copenhagen under the symbol ‘NOVO B’. Its ADRs are listed on the New York Stock Exchange under the symbol ‘NVO’. For further company information, visit Novo Nordisk on: www.novonordisk.com Upcoming events 28 June 2021 R&D investor call in connection with ADA 05 August 2021 Financial statement for the first six months of 2021 03 November 2021 Financial statement for the first nine months of 2021 02 February 2022 Financial statement for 2021 ADA: American Diabaetes Association
Download PDF file